GNBT News and Press, Generex Biotechnology From 10/02/20

Closing of licensing & distribution agreement with Bintai for COVID-19 vaccine in Malaysia Update on Ii-Key-SARS-CoV-2 vaccine development & international licensing opportunities COVID-19 Vaccine Scientific & Clinical Advisory Board Planed application to list NuG...

Generex Biotechnology's ([[GNBT]] +18.0%) newly formed subsidiary NuGenHealth has signed a contract with Paradise Valley Family Medicine for providing connected care solutions for patient engagement, Remote Patient Monitoring and Chronic Care Management services.NuGenHealth is a JV betwe...

-  NuGenHealth Software as a Service (SaaS) platform launch -  PVFM responds to COVID-19 with connected care solutions to serve their Medicare patient population MIRAMAR, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) announce...

Generex Biotechnology ( OTCQB:GNBT ) and Bintai Kinden of Malaysia have agreed to collaborate for the development of the Ii-Key-CoV-2 vaccine for Malaysia. More news on: Generex Biotechnology Corporation, Healthcare stocks news, Read more ...

Bintai Kinden Corporation Berhad (www.bintai.com.my) is an investment holding company headquartered in Malaysia with operations throughout South-East Asia, China, and the Arabian Gulf Region Upfront licensing fee of $2.5 million 100% funding for development, manufacturing and commercial ...

Japanese High In 1989, the Japanese Nikkei hit 38,916. It was a time of craziness. The Emperor's palace was valued at equal to all of the real estate in California. Such prices are unsustainable. The Nikkei 30 years out sits at 23,205. Someday, the high point of the Nikkei will be surpassed,...

Article Published on September 8, 2020: Title: “Generex Biotechnology's COVID-19 Vaccine Could Outperform Competition” To view the report, go to: https://seekingalpha.com/article/4373034 MIRAMAR, Fla., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corpor...

Below I will briefly touch on leading COVID-19 vaccine competitors, before diving into common issues each of these leading vaccine products have. Fortunately, a COVID-19 vaccine from NuGenerex Immuno-Oncology, AKA NGIO, a subsidiary of thinly-traded Generex Biotechnology ( GNBT ), will likel...

MIRAMAR, Fla., Aug. 27, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology ( NGIO ) today announced that it has cancelled the investor conference call originally scheduled to be held, Thursday, August 27, 2020 at 9:30 am. The conference call has been cancelled because the updates on the ...

The NuGenHealth Software as a Service (SaaS) System Remote Patient Monitoring (RPM) Chronic Care Management (CCM) The access information for the investor conference call remains as follows: Direct Toll / International – 1-(866) 831-8711 Domestic US/Canada - 1-(203) 518-9883 P...